NCT00408967 is a Phase 2 clinical trial of Tucotuzumab celmoleukin (EMD 273066) in Ovarian Cancer, sponsored by EMD Serono.

Who is sponsoring NCT00408967?

NCT00408967 is sponsored by EMD Serono.

What drugs are being tested in NCT00408967?

Interventions in NCT00408967: Tucotuzumab celmoleukin (EMD 273066).

What condition does NCT00408967 study?

NCT00408967 studies Ovarian Cancer.

Is NCT00408967 still recruiting?

NCT00408967 is currently withdrawn. Last updated 18 August 2017.

Last reviewed 2017-08-18 · How we verify

NCT00408967

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.

Withdrawn Phase 2 Last updated 18 August 2017

What this trial tests

Phase 2 trial testing Tucotuzumab celmoleukin (EMD 273066) in Ovarian Cancer. Withdrawn.

Timeline

31 December 2006

Primary endpoint
31 May 2008

31 May 2008

Quick facts

Lead sponsor	EMD Serono
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Start date	31 December 2006
Primary completion	31 May 2008
Estimated completion	31 May 2008

Drugs / interventions tested

Tucotuzumab celmoleukin (EMD 273066) — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

EMD Serono — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if either of two doses of EMD 273066 when given with a low dose of cyclophosphamide will result in a second time to progression that is as long or longer than the first time to progression

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
Young PA, Morrison SL, Timmerman JM. · · 2014 · cited 54× · PMID 25440607 · DOI 10.1053/j.seminoncol.2014.08.002
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion.
Wu Y, Wu Y, Gao Z, Yu W, et al · · 2026 · cited 2× · PMID 41484095 · DOI 10.1038/s41392-025-02327-3

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other EMD Serono trials

Trials by the same sponsor.

NCT02070978 — Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II) · Phase 2 · terminated
NCT01971515 — First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies · Phase 1 · completed
NCT01992874 — Relative Bioavailability of Pimasertib in Cancer Patients · Phase 1 · completed
NCT01936363 — Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer · Phase 2 · completed
NCT01693068 — Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00408967 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by EMD Serono
Last refreshed: 18 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00408967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing